Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertriglyceridemia and cardiovascular risk reduction.

Terry A Jacobson1, Michael Miller2, Ernst J Schaefer3

  • 1Office of Health Promotion and Disease Prevention, Emory University, Atlanta, Georgia, USA.

Clinical Therapeutics
|August 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review.

Current atherosclerosis reports·2025
Same author

Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project.

Journal of the American Heart Association·2025
Same author

Low-density lipoprotein cholesterol elevation, ketogenic diets, body mass index, and heterozygous ABCG5 genetic variation: Review, case report, and large population analysis.

Journal of clinical lipidology·2025
Same author

Impact of NAFLD-related SNPs on the carotid atherosclerosis development; a five-year prospective observational study.

Atherosclerosis plus·2025
Same author

High-density lipoprotein infusion therapy: A review.

Journal of clinical lipidology·2024
Same author

Genetically and clinically confirmed atypical cerebrotendinous xanthomatosis with normal cholestanol and marked elevations of bile acid precursors and bile alcohols.

Journal of clinical lipidology·2024
Same journal

Early Feasibility Studies in Europe: A Multisite Qualitative Study of Operational Challenges and Site Selection Determinants at 6 University Hospitals.

Clinical therapeutics·2026
Same journal

Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database.

Clinical therapeutics·2026
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
See all related articles

High triglyceride levels are common and may increase coronary heart disease risk. Managing triglyceride (TG) levels with lifestyle changes and medications is crucial for reducing this risk.

Area of Science:

  • Cardiology
  • Endocrinology
  • Public Health

Background:

  • Elevated triglyceride (TG) levels are prevalent in the US, associated with obesity, type 2 diabetes, and metabolic syndrome.
  • High TG levels are an independent risk factor for coronary heart disease (CHD), especially in women.

Purpose of the Study:

  • Review epidemiology, risks, and prevention of hypertriglyceridemia.
  • Outline recommended TG goals and available TG-lowering agents.

Main Methods:

  • Searched MEDLINE (1990-2006) for hypertriglyceridemia, dyslipidemia, and CHD.
  • Reviewed articles on TG epidemiology, CHD risk, treatment guidelines, and clinical trials of TG-lowering drugs.

Main Results:

  • Recent guidelines reflect concern over rising hypertriglyceridemia rates.

Related Experiment Videos

  • Available TG-lowering agents include statins, fibrates, niacin, thiazolidinediones, and omega-3 fatty acids.
  • Clinical trials show TG reduction from 7% to 50% with these agents; combination therapy may be effective.

    • Conclusions:

    • Managing TG levels, alongside LDL cholesterol, is essential for reducing CHD risk.
    • Integrated strategies are needed for effective lipid management in dyslipidemia.